Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: RNA-sequencing analysis of human fibrolamellar hepatocellular carcinoma and 4 maturational stages of the human hepatobiliary system

PROVIDER: PRJNA296091 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR2430370_1.fastq.gz	Fastqsanger.gz
	SRR2430370_2.fastq.gz	Fastqsanger.gz
	SRR2430380_1.fastq.gz	Fastqsanger.gz
	SRR2430380_2.fastq.gz	Fastqsanger.gz
	SRR2430371_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

RNA-sequencing analysis of human fibrolamellar hepatocellular carcinoma and 4 maturational stages of the human hepatobiliary system

Project description:The etiology of fibrolamellar hepatocellular carcinoma (FL-HCC), a liver cancer occurring increasingly in children to young adults, is poorly understood. We performed high-throughput sequencing on mRNA isolated from a newly developed model of FL-HCC and 4 different maturational lineages of the hepatobiliary system. Our results indicate that the transcriptome of FL-HCC is most similar to that of biliary tree stem cells.

2015-10-06 | GSE73114 | GEO

Small RNA-sequencing of primary fibrolamellar carcinoma (FLC), FLC patient-derived xenograft, and maturational liver lineage stages

Project description:Fibrolamellar carcinoma (FLC) is a rare liver cancer. Here we characterized the small RNA expression landscape of primary FLC, a FLC patient-derived xenograft model, and normal maturational liver lineage stages

2019-03-07 | GSE114974 | GEO

Homo sapiens

Project description:GENOMIC ANALYSIS OF FIBROLAMELLAR HEPATOCELLULAR CARCINOMA

| PRJNA242221 | ENA

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Project description:The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKACA fusion transcript in fibrolamellar hepatocellular carcinoma. DNAJB1-PRKACA-derived HLA class I and HLA class II ligands induce multifunctional cytotoxic CD8+ and T-helper 1 CD4+ T cells, and their cellular processing and presentation in DNAJB1-PRKACA expressing tumor cells is demonstrated by mass spectrometry-based immunopeptidome analysis. Single-cell RNA sequencing further identifies multiple T cell receptors from DNAJB1-PRKACA-specific T cells. Vaccination of a fibrolamellar hepatocellular carcinoma patient, suffering from recurrent short interval disease relapses, with DNAJB1-PRKACA-derived peptides under continued Poly (ADP-ribose) polymerase inhibitor therapy induces multifunctional CD4+ T cells, with an activated T-helper 1 phenotype and high T cell receptor clonality. Vaccine-induced DNAJB1-PRKACA-specific T cell responses persist over time and, in contrast to various previous treatments, are accompanied by durable relapse free survival of the patient for more than 21 months post vaccination. Our preclinical and clinical findings identify the DNAJB1-PRKACA protein as source for immunogenic neoepitopes and corresponding T cell receptors and provide efficacy in a single-patient study of T cell-based immunotherapy specifically targeting this oncogenic fusion.

2022-10-13 | PXD029882 | Pride

Small RNA-sequencing of primary fibrolamellar carcinoma (FLC), FLC patient-derived xenograft, and maturational liver lineage stages

Project description:Small RNA-sequencing of primary fibrolamellar carcinoma (FLC), FLC patient-derived xenograft, and maturational liver lineage stages

| PRJNA473423 | ENA

A Therapeutic Vaccine for Fibrolamellar Hepatocellular Carcinoma

Project description:A Therapeutic Vaccine for Fibrolamellar Hepatocellular Carcinoma

| PRJNA1234708 | ENA

A Therapeutic Vaccine for Fibrolamellar Hepatocellular Carcinoma

Project description:A Therapeutic Vaccine for Fibrolamellar Hepatocellular Carcinoma

| PRJNA1234707 | ENA

CIT-CHEF

Project description:Fibrolamellar hepatocellular carcinoma (FLC) is a rare type of primary liver cancer that often arises in children, adolescents and young adults. At the pathological level, FLC display pure morphology or can present with mixed morphology involving a conventional HCC component. Owing to the rarity of the disease, its genetic landscape is fully unknown. Pure FLC showed less chromosomic aberrations than mixed FLC and hepatocellular carcinoma arising in non-cirrhotic liverﾵ. Nevertheless; they displayed more gains in 16q23 and more LOH in 21q22. We also analyzed the mutational landscape of 8 FLC by whole-exome sequencing and showed mutations in the coagulation pathway.

2015-06-15 | E-MTAB-2675 | biostudies-arrayexpress

The Genome and Transcriptome of Fibrolamellar Hepatocellular Carcinoma

Project description:<p>Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare liver tumor primarily affecting adolescents and young adults. Little is known of the molecular pathogenesis. To characterize the disease we performed RNA sequencing and whole genome sequencing on FL-HCC tumors and adjacent normal tissue. The results demonstrate few consistent differences on the chromosomal level and many hundreds of alterations in the expression of RNA transcripts.</p>

| phs000709 | dbGaP

Human Bile LC-MS/MS - One Sample, One Shot - Evaluation of sample preparation protocols for the mass spectrometric proteome analysis of human bile fluid without extensive fractionation

Project description:The proteome analysis of bile fluid represents a promising strategy to identify biomarker candidates for various diseases of the hepatobiliary system. However, to obtain substantive results in biomarker discovery studies large patient cohorts necessarily need to be analyzed. Consequently, this would lead to an unmanageable number samples to be measured if sample preparation protocols with extensive fractionation methods are applied. Hence, the performance of simple workflows allowing for "one sample, one shot" experiments have been evaluated in this study. In detail, sixteen different protocols implying modifications at the stages of desalting, delipidation, deglycosylation and tryptic digestion have been tested. Each method has been individually evaluated regarding various performance criteria and comparative analyses have been conducted to uncover possible complementarities. Here, the best performance in terms of proteome coverage has been assessed for a combination of acetone precipitation with in-gel digestion. Finally, a mapping of all obtained protein identifications with putative biomarkers for hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC) revealed several proteins easily detectable in bile fluid. These results can build the basis for future studies with large and well-defined patient cohorts in a more disease-related context, instead of a technical one as reported here.

2017-05-03 | PXD004476 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data